Tianlongkechuanling Inhibits Pulmonary Fibrosis Through Down-Regulation of Arginase-Ornithine Pathway

Background: Pulmonary Fibrosis (PF) is an interstitial lung disease characterized by excessive accumulation of extracellular matrix in the lungs, which disrupts the structure and gas exchange of the alveoli. There are only two approved therapies for PF, nintedanib (Nib) and pirfenidone. Therefore, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lili, Qu, Sihao, Wang, Lu, Wang, Chunguo, Yu, Qinghe, Zhang, Zhimin, Diao, Yirui, Zhang, Binbin, Li, Yadong, Shi, Yuanyuan, Wang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114272/
https://www.ncbi.nlm.nih.gov/pubmed/33995084
http://dx.doi.org/10.3389/fphar.2021.661129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114272/
https://www.ncbi.nlm.nih.gov/pubmed/33995084
http://dx.doi.org/10.3389/fphar.2021.661129

Ejemplares similares